{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:35:56Z","timestamp":1763116556323,"version":"3.30.1"},"reference-count":14,"publisher":"Medknow","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Res Pharm Pract"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/jrpp.jrpp_17_36","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:57:01Z","timestamp":1505955421000},"page":"182","source":"Crossref","is-referenced-by-count":8,"title":["Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: A case report"],"prefix":"10.4103","volume":"6","author":[{"given":"Azadeh","family":"Moghaddas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzaneh","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Derakhshandeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijan","family":"Movahedian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2581","reference":[{"key":"key-10.4103\/2279-042X.215233-1","first-page":"925","volume-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: New horizons in oncology","author":"Fusco","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"key-10.4103\/2279-042X.215233-2","first-page":"826","volume-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2279-042X.215233-3","first-page":"1774","volume-title":"SU14813: A novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity","author":"Patyna","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"key-10.4103\/2279-042X.215233-4","first-page":"1532","volume-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","author":"Smidt-Hansen","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/2279-042X.215233-5","first-page":"321","volume-title":"Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib","author":"Bozas","year":"2010","journal-title":"Oncol Res Treat"},{"key":"key-10.4103\/2279-042X.215233-6","first-page":"1665","volume-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"key-10.4103\/2279-042X.215233-7","first-page":"173","volume-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"key-10.4103\/2279-042X.215233-8","first-page":"e1","volume-title":"Sunitinib related osteonecrosis of jaw: A case report","author":"Fleissig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"key-10.4103\/2279-042X.215233-9","first-page":"209","volume-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"key-10.4103\/2279-042X.215233-10","first-page":"181","volume-title":"Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/2279-042X.215233-11","first-page":"463","volume-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of three cases","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"key-10.4103\/2279-042X.215233-12","first-page":"4037","volume-title":"Osteonecrosis of the jaw related to bevacizumab","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/2279-042X.215233-13","first-page":"158","volume-title":"Osteosarcoma of the jaw bones","author":"Slootweg","year":"1985","journal-title":"J Maxillofac Surg"},{"key":"key-10.4103\/2279-042X.215233-14","first-page":"239","volume-title":"Amethod for estimating the probability of adverse drug reactions","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:58:47Z","timestamp":1505955527000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrpp.net\/text.asp?2017\/6\/3\/182\/215233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["215233"],"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_17_36","relation":{},"ISSN":["2279-042X"],"issn-type":[{"type":"print","value":"2279-042X"}],"subject":[],"published":{"date-parts":[[2017]]}}}